There are currently 446 clinical trials in Kansas City, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kansas Medical Center, University of Kansas Cancer Center, Kansas University Medical Center and Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Behavior and Post-operative Outcomes
NCT06576661
Recruiting
The goal of this study is to evaluate the influence of real-time intrarenal pressure measurement availability on surgeons' behavior during ureteroscopy while using the ureteroscope LithoVue Elite.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Kidney Stone, Nephrolithiasis
Register for Updates
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200
Recruiting
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
07/30/2025
Locations: Kansas University Medical Center, Kansas City, Kansas
Conditions: Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Kansas City, Kansas
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
Pulmonary Hypertension Biorepository and Registry
NCT04808596
Recruiting
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Register for Updates
Post COVID-19 Biorepository
NCT04885504
Recruiting
Establish a biorepository, clinical data registry, and radiographic image database from individuals who were COVID positive at one time and are being seen for outpatient follow-up or a separate study visit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Coronavirus Infection
Register for Updates
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic, Kansas City, Kansas
Conditions: Primary Biliary Cholangitis (PBC)
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/29/2025
Locations: Research Site, Kansas City, Kansas
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT06184750
Recruiting
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 55 years
Trial Updated:
07/29/2025
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Chronic Spontaneous Urticaria
Register for Updates
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Parkinson Disease
Register for Updates
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
NCT06891755
Recruiting
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study su... Read More
Gender:
ALL
Ages:
Between 40 years and 84 years
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center Research Institute, Kansas City, Kansas
Conditions: COPD, Emphysema
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: KU Medical Center, Kansas City, Kansas
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates